[go: up one dir, main page]

ATE346078T1 - Verfahren zur herstellung von 4'- azidonukleosidderivaten - Google Patents

Verfahren zur herstellung von 4'- azidonukleosidderivaten

Info

Publication number
ATE346078T1
ATE346078T1 AT04739843T AT04739843T ATE346078T1 AT E346078 T1 ATE346078 T1 AT E346078T1 AT 04739843 T AT04739843 T AT 04739843T AT 04739843 T AT04739843 T AT 04739843T AT E346078 T1 ATE346078 T1 AT E346078T1
Authority
AT
Austria
Prior art keywords
alkyl
azidonucleoside
halogen
hydrogen
group
Prior art date
Application number
AT04739843T
Other languages
English (en)
Inventor
Terrence Joseph Connolly
Kieran Durkin
Keshab Sarma
Jiang Zhu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE346078T1 publication Critical patent/ATE346078T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04739843T 2003-06-19 2004-06-11 Verfahren zur herstellung von 4'- azidonukleosidderivaten ATE346078T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47979603P 2003-06-19 2003-06-19

Publications (1)

Publication Number Publication Date
ATE346078T1 true ATE346078T1 (de) 2006-12-15

Family

ID=33551901

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04739843T ATE346078T1 (de) 2003-06-19 2004-06-11 Verfahren zur herstellung von 4'- azidonukleosidderivaten

Country Status (14)

Country Link
US (1) US20050038240A1 (de)
EP (1) EP1644395B1 (de)
JP (1) JP2006527719A (de)
KR (1) KR20060026426A (de)
CN (1) CN1809582A (de)
AT (1) ATE346078T1 (de)
CA (1) CA2528294A1 (de)
DE (1) DE602004003389T2 (de)
DK (1) DK1644395T3 (de)
ES (1) ES2276311T3 (de)
IL (1) IL172275A0 (de)
MX (1) MXPA05013452A (de)
TW (1) TW200519122A (de)
WO (1) WO2005000864A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
EP1536804A4 (de) * 2002-06-28 2007-10-31 Idenix Cayman Ltd 2'-c-methyl-3'-o-l-valinester-ribofuranosylcytidin zur behandlung von flaviviridae-infektionen
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
JP2006519753A (ja) * 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
US7598373B2 (en) * 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
WO2006119061A2 (en) * 2005-05-02 2006-11-09 Merck & Co., Inc. Hcv ns3 protease inhibitors
AR057456A1 (es) * 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
JP4705984B2 (ja) * 2005-08-01 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド
JP5254033B2 (ja) * 2005-12-23 2013-08-07 イデニク プハルマセウティカルス，インコーポレイテッド 分岐型ヌクレオシドを調製するための合成中間体の製造方法
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) * 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
MX2009003452A (es) * 2006-10-10 2009-04-14 Medivir Ab Inhibidores nucleosidicos del vhc.
US8377873B2 (en) * 2006-10-24 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8309540B2 (en) * 2006-10-24 2012-11-13 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
EP2079479B1 (de) * 2006-10-24 2014-11-26 Merck Sharp & Dohme Corp. Inhibitoren der hcv-ns3-protease
BRPI0718161A2 (pt) 2006-10-27 2013-11-26 Merck & Co Inc Composto, composição farmacêutica, e, uso do composto.
JP5352464B2 (ja) * 2006-10-27 2013-11-27 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
CA2671306C (en) 2006-12-11 2011-04-19 F. Hoffmann-La Roche Ag Process for preparation of 4'-azido cytidine derivatives
GB0625345D0 (en) * 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2010513450A (ja) * 2006-12-20 2010-04-30 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス性インドール
GB0625349D0 (en) * 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
PL2144604T3 (pl) * 2007-02-28 2012-02-29 Conatus Pharmaceuticals Inc Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830
AU2008277442A1 (en) * 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
AU2008277377B2 (en) * 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
US8461107B2 (en) * 2008-04-28 2013-06-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP2011526893A (ja) * 2008-07-02 2011-10-20 イデニク プハルマセウティカルス，インコーポレイテッド ウイルス感染の治療のための化合物、及び医薬組成物
KR101313675B1 (ko) * 2008-07-22 2013-10-02 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티 에스.알.엘. Ｈｃｖ ｎｓ3 프로테아제 억제제로서의 마크로사이클릭 퀴녹살린 화합물
WO2010068708A2 (en) 2008-12-09 2010-06-17 Rfs Pharma, Llc 3'-azido purine nucleotide prodrugs for treatment of viral infections
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
KR20110099138A (ko) 2008-12-23 2011-09-06 파마셋 인코포레이티드 뉴클레오시드 포스포르아미데이트
CA2748016A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
EP2393815A4 (de) 2009-02-06 2012-11-21 Rfs Pharma Llc Purin-nukleosid-monophosphat-prodrugs zur behandlung von krebs und virusinfektionen
EP2403860B1 (de) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene und phosphothiazole als hcv polymerase inhibitoren
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
EP2459211A1 (de) 2009-07-31 2012-06-06 Medtronic, Inc. Kontinuierliche subkutane verabreichung von interferon an hepatitis-c-patienten
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
TW201136942A (en) 2009-12-18 2011-11-01 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
AR094621A1 (es) 2010-04-01 2015-08-19 Idenix Pharmaceuticals Inc Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
US8877731B2 (en) 2010-09-22 2014-11-04 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039855A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
EP2780026B1 (de) 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Hcv-ns3 -proteasehemmer
BR112014013224B1 (pt) 2011-11-30 2023-03-07 Emory University Inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais
US20130217644A1 (en) 2012-02-13 2013-08-22 Idenix Pharmaceuticals, Inc. Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
CN104470939B (zh) 2012-05-22 2017-04-26 埃迪尼克斯医药有限责任公司 用于肝脏疾病的d型氨基酸化合物
EP2852605B1 (de) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclische phosphat-prodrugs für hcv-infektion
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
CA2887578A1 (en) 2012-10-08 2014-04-17 Idenix Pharamaceuticals, Inc. 2'-chloro nucleoside analogs for hcv infection
EP2909223B1 (de) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinukleotidverbindungen für hcv-infektion
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
EP2935304A1 (de) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluor-nukleoside zur behandlung von hcv
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
EP2970358B1 (de) 2013-03-04 2021-06-30 Idenix Pharmaceuticals LLC 3'-deoxy-nukleoside zur behandlung von hcv
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
EP3027636B1 (de) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotide of halogenierte pyrimidine verbindungen für leber krankheiten
EP3046924A1 (de) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Inhibitoren des hepatitis-c-virus
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
US20170198005A1 (en) 2013-11-27 2017-07-13 Idenix Pharmaceuticals Llc 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
WO2015095419A1 (en) 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 4'-or nucleosides for the treatment of hcv
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
EP3114122A1 (de) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Feste formen einer flaviviridae-virus-hemmerverbindung und salze davon
EP3131914B1 (de) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituierte methyl- oder alkynylnukleoside zur behandlung von hcv
IL295418B2 (en) 2015-03-06 2023-10-01 Atea Pharmaceuticals Inc Cell-D-2'-deoxy-2'-alpha-fluoro-2'-cell-C-modified-2-different-N6-purine modified nucleotides for the treatment of hepatitis C virus
KR20220146668A (ko) 2016-09-07 2022-11-01 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
ES3009733T3 (en) 2017-02-01 2025-03-31 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
TW202012001A (zh) 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6363668A (ja) * 1986-09-04 1988-03-22 Yuki Gosei Yakuhin Kogyo Kk ５−メチルピリミジン誘導体の製造法
JP2002517474A (ja) * 1998-06-10 2002-06-18 グリコデザイン インコーポレイテッド 定方向のコンビナトリアル化合物ライブラリおよびそれをスクリーニングするための高スループットアッセイ
KR100660754B1 (ko) * 2001-04-30 2006-12-26 트롬스도르프 게엠베하 운트 코. 카게 알츠나이미텔 의약적으로 활성인 우리딘 에스테르
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
DE602005015466D1 (de) * 2004-08-23 2009-08-27 Hoffmann La Roche Antivirale 4'-azidonucleoside

Also Published As

Publication number Publication date
EP1644395B1 (de) 2006-11-22
JP2006527719A (ja) 2006-12-07
IL172275A0 (en) 2006-04-10
MXPA05013452A (es) 2006-03-09
EP1644395A1 (de) 2006-04-12
DE602004003389D1 (de) 2007-01-04
TW200519122A (en) 2005-06-16
WO2005000864A1 (en) 2005-01-06
KR20060026426A (ko) 2006-03-23
ES2276311T3 (es) 2007-06-16
US20050038240A1 (en) 2005-02-17
DK1644395T3 (da) 2007-04-02
CA2528294A1 (en) 2005-01-06
CN1809582A (zh) 2006-07-26
DE602004003389T2 (de) 2007-09-13

Similar Documents

Publication Publication Date Title
ATE346078T1 (de) Verfahren zur herstellung von 4'- azidonukleosidderivaten
ATE346062T1 (de) Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten
EA200500268A1 (ru) Производные диоксан-2-алкилкарбаматов, способ их получения и применение в терапии
ATE253581T1 (de) Verfahren zur herstellung von 3,4- alkylendioxythiophen-2,5-dicarbonsäurederivaten
FI971312A0 (fi) Uudet prostaglandiinisyntaasin estäjät
DE69712784D1 (de) Säureadditionssalze einer optisch aktiven piperidinverbindung und verfahren zu seiner herstellung
DE60237128D1 (de) Verfahren zur Herstellung von Isopulegol
EA200400129A1 (ru) Способ получения периндоприла, его аналогов и солей с использованием 2,5-диоксооксазолидиновых промежуточных соединений
DE60233664D1 (de) Verfahren zur herstellung von pyridinverbindungen
IS6435A (is) Aðferð til framleiðslu á sítalóprami
ATE359272T1 (de) Verfahren zur herstellung von 3-hydroxy-n-1,6-
WO2004094435A3 (en) Siloxane monomers and oligomers
ATE191461T1 (de) Verfahren zur herstellung von alkoxyimino acetamid-derivaten
RU2000126750A (ru) Способы получения промежуточных соединений
ATE299862T1 (de) Verfahren zur herstellung von ketiminen
ATE368035T1 (de) Herstellung von phthalanen
ATE363460T1 (de) Verfahren zur herstellung von fluorhalogenalkanen
EE200300090A (et) Asendatud imidasopüridiinühendite valmistamise meetod
ATE194980T1 (de) Verfahren zur herstellung von alkylimidazolidinon(meth)acrylates
ATE222902T1 (de) Verfahren zur herstellung von hetero-bizyklischem alkohol-enantiomer
DE69407783D1 (de) Verfahren zur herstellung von p-alkyl- und p-arylsulfonylbenzoesäure-derivate
DK11788D0 (da) Stereobevarende syntese af 1-substituerede (s)- og (r)-2-aminometylpyrrolidiner og mellemprodukter dertil
ATE528358T1 (de) Verfahren zur herstellung einer azoverbindung
DK1581504T3 (da) Fremgangsmåde til fremstilling af subsituterede imidazolderivater og intermediater anvendt i fremgangsmåden
ATE479661T1 (de) Verfahren zur herstellung von pestiziden verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1644395

Country of ref document: EP

REN Ceased due to non-payment of the annual fee